Related Experiment Videos
Pentoxifylline in end-stage renal disease
1Department of Medicine, University of Pittsburgh, PA 15261.
Drug Intelligence & Clinical Pharmacy
|December 1, 1987
Summary
Pentoxifylline clearance is poorly understood in renal failure. In a dialysis patient, a reduced dose led to toxicity, with prolonged drug half-life and high metabolite levels, indicating impaired drug elimination.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Toxicology
Background:
- Limited data exists on pentoxifylline and its metabolite clearance in patients with renal failure.
- Renal impairment can significantly alter drug pharmacokinetics, necessitating dose adjustments.
Observation:
- A patient undergoing dialysis required pentoxifylline treatment.
- Dosage was initiated low and gradually increased, with close monitoring for toxicity and plasma drug concentrations.
Findings:
- The patient exhibited signs of pentoxifylline toxicity on two-thirds of the standard adult dose.
- Pentoxifylline and its primary metabolite (metabolite I) showed substantially prolonged half-lives compared to healthy individuals.
- Rapid accumulation of pentoxifylline and high concentrations of metabolites IV and V were observed in plasma.
Implications:
- This case highlights the potential for pentoxifylline accumulation and toxicity in renal failure patients.
- Careful dose titration and therapeutic drug monitoring are crucial when prescribing pentoxifylline to dialysis patients.
- Further research is warranted to establish safe and effective dosing guidelines for pentoxifylline in renal impairment.